FISHAWACK
1.8.2019 15:02:09 CEST | Business Wire | Press release
2e Creative , an internationally recognised healthcare marketing strategy firm focused on launching pharmaceutical and medical device products, has joined the Fishawack Group , after receiving investment from the global healthcare communications group. The 2e deal strengthens Fishawack as one of the largest independent healthcare communications organisations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005540/en/
“2e has been on an exhilarating growth trajectory for the past several years,” 2e CEO Ross Toohey said. “We chose Fishawack over a host of other potential investors because their global footprint, expansive capabilities, and entrepreneurial culture represented the greatest advantage for our employees and clients. This is truly the next evolutionary leap for 2e and the brands we serve.”
Fishawack is a global healthcare communications group with offices in London, Oxford, Brighton and Manchester, UK, as well as Philadelphia, New York, and San Diego, USA; 2e adds to the group’s US footprint. The firm’s core strengths in medical communications, strategic consulting, and creative, fits nicely with 2e’s expertise in strategy, creative, digital marketing, sales training, and internal communications. With this breadth of capabilities, Fishawack and 2e can now support clients throughout the entire product development, launch, and growth lifecycle. With the 2e partnership, the Fishawack Group now boasts over 750 employees worldwide, making it among the largest independent healthcare agencies globally.
“Fishawack is one of the new generation of leaders in healthcare communications. We’re challenging the major agency networks by fostering a uniquely collaborative culture across our agency collective,” Fishawack CEO Oliver Dennis said. “We offer the capabilities, scale, and geographical coverage to offer healthcare brands a fresh, new type of partnership value. We’re excited about 2e’s portfolio, capabilities, and brilliant people. Ross has built a great entrepreneurial culture, and we can’t wait to work with the 2e team.”
This partnership is particularly notable for 2e because it comes on the heels of the agency’s appointment to the MM&M Top 100 Healthcare Agencies worldwide, as well as 2e’s three consecutive victories (2015, 2016, 2017) as MM&M “Healthcare Agency of the Year.” Between 2e and sister agencies Dudnyk , Carling Communications , Blue Latitude Health , and Healthcircle , the Fishawack Group is among the most award winning in the field of healthcare marketing.
“We’re very deliberate about the agencies we invest in,” Fishawack Group President Gail Flockhart said. “Clients demand seamlessly blended capabilities, so it’s important that we build collaborative allegiances across the Fishawack Group. It’s best for our clients and our people. 2e brings executive training and organisational optimisation capabilities to the group.”
Advisors to Fishawack included KPMG, Addleshaw Goddard LLP, and financial backers LDC and LGT Capital Partners. 2e’s advisors included Results International, Stoll Keenon Ogden PLLC, and Clifton Larson Allen.
About 2e Creative
Founded in 1999, 2e Creative is a launch and growth agency featuring Fortune 50 clients across pharma, medical device, and research biotech. The agency’s core competencies include branding, marketing strategy, digital marketing, sales training, and meeting/event production. 2e has over 150 employees and operations in Missouri, Indiana, Texas, and California.
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Manchester, Oxford, London, and Brighton), the USA (Philadelphia, PA, New York, NY, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
Fishawack comprises two international divisions, Fishawack Medical Communications , developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative , offering strategic planning, creative development, advertising and promotion, and tactical execution.
We have built our reputation on excellence, creativity, and transparency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
